We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tapinarof: A novel topical agent for psoriasis.
- Authors
Jaleel, Neethu; Navya, V; George, Mamatha
- Abstract
Tapinarof is a novel topical agent that has been approved by the United States Food and Drug Administration (US FDA) for the treatment of plaque psoriasis in adults. It acts as an AhR modulator, downregulating the expression of IL-17 and IL-22, inducing the expression of skin barrier genes, and reducing oxidative stress. Tapinarof is derived from the gram-negative bacteria Photorhabdus luminescens and is available as a 1% cream. Clinical trials have shown its efficacy in improving psoriasis symptoms, and further studies are underway to assess its safety and effectiveness in other conditions and populations.
- Subjects
PHOTORHABDUS luminescens; PSORIASIS; GRAM-negative bacteria; OXIDATIVE stress; INTERLEUKIN-17
- Publication
Indian Dermatology Online Journal, 2023, Vol 14, Issue 6, p916
- ISSN
2229-5178
- Publication type
Article
- DOI
10.4103/idoj.idoj_309_23